Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2026.
Impact
The bill fundamentally amends existing insurance regulations as stipulated under Chapter 27-18 of the General Laws related to accident and sickness insurance policies. It requires health insurance plans issued or renewed in Rhode Island to provide coverage for certain diabetes-related equipment, including blood glucose monitors, insulin syringes, and pumps. This legislative change could substantially improve healthcare access for diabetic patients, particularly those who may face financial barriers due to high out-of-pocket costs for these supplies. The effective date of January 1, 2026, suggests a planned implementation to allow health plans time to adjust their policies accordingly.
Summary
House Bill H5026 aims to address the high costs associated with diabetes management by capping the amount a covered person needs to pay for insulin administration and glucose monitoring supplies. Specifically, the bill mandates that from January 1, 2026, individuals will pay no more than $25 for a 30-day supply of the necessary equipment and supplies. Importantly, this coverage will not have any deductible, promoting better access to critical diabetes management resources for those affected by this condition. The bill is a significant legislative step towards making diabetes care more financially accessible for residents of Rhode Island.
Contention
While the bill enjoys support from various healthcare advocates who assert that it alleviates financial distress on individuals managing diabetes, there may be potential contention surrounding its implementation. Concerns may arise regarding how this cap will affect overall insurance premiums or whether it could lead to coverage limitations in other areas. Additionally, while the bill is designed to improve affordability, it will require health plans to adjust to regulatory changes that ensure compliance with the new cost cap, potentially inciting discussions around the sustainability of such mandates in the long term.
Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2025.
Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2025.
Amends tax law on renewable energy products to exempt certain additional products from sales tax including battery energy storage system equipment, if supplied by a manufacturer of solar photovoltaic equipment.
Caps the total amount that a covered person is required to pay for a covered prescription asthma inhaler to twenty-five dollars ($25.00) per thirty (30) day supply.
Limits copays, coinsurance or office deductibles for services of a physical therapist to the amount authorized for the services of a primary care physician or osteopath on or after January 1, 2025.
Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2026.
Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2025.
Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2025.